GTMB 7 - Gene Therapy & Molecular Biology

Kairemo et al: Oligonucleotide radiotherapylevel. Medical Internal Radiation Dose Committee. J NuclMed 40, 11S-36S.Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA. (1997)Inhibition of vascular endothelial growth factor-inducedendothelial cell migration by ETS1 antisenseoligonucleotides. Cancer Res 57, 2013-9Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT,Manseau EJ, Dvorak HF. (1996) Expression of vascularpermeability factor/vascular endothelial growth factor bymelanoma cells increases tumor growth, angiogenesis, andexperimental metastasis. Cancer Res 56, 172-81Crooke RM, Graham MJ, Cooke ME, Crooke ST. (1995) In vitropharmacokinetics of phosphorothioate antisenseoligonucleotides. J Pharmacol Exp Ther 275, 462-473.Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS,Cummins LL, Greig MJ, Guinosso CJ, Kornburst D,Manorahan M, Sasmor HM, Schleich T, Tivel KL, GriffeyRH. (1996) Pharmacokinetic properties of several noveloligonucleotide analogs in mice. J Pharmacol Exp Ther277, 923-937Dewanjee M.K, Ghafouripour A.K, Kapadvanjwala M,Dewanjee S, Serafini AN, Lopez DM, and Sfakianakis GN.(1994a) Noninvasive imaging of c-myc oncogene messengerRNA with indium-111-antisense probes in a mammarytumor-bearing mouse model. J. Nucl. Med. 35, 1054-1063.Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM,Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE.(1993) PNA hybridizes to complementary oligonucleotidesobeying the Watson-Crick hydrogen-bonding rules. Nature365, 566-568.Egholm M, Burchardt O, Nielsen PE, Berg RH. (1992) Peptidenucleic acids (PNA), oligonucleotide analogs with an achiralpeptide backbone. J Am Chem Soc 114, 1895-1897.Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, GendelmanR, Raffeld M, Zon G, Gallo RC. (1994) Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesionformation in nude mice by antisense oligonucleotidetargeting basic fibroblast growth factor. A novel strategy forthe therapy of KS. J Clin Invest 94, 1736-46Geselowitz DA, Neckers LM. (1992) Analysis of oligonucleotidebinding, internalization and intracellular trafficking utilizinga novel radiolabeled crosslinker. Antisense Res Dev 2, 17-25.Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT.(1996) Subcutaneous injection of a cyclic peptide antagonistof vitronectin receptor-type integrins inhibits retinalneovascularization. Nat Med. 2, 529-33.Hanahan D. (1997) Signaling vascular morphogenesis andmaintenance. Science 277, 48-50.Iversen PL, Mata J, Tracewell WG, and Zon G. (1994)Pharmacokinetics of an antisense phosphorothioateoligodeoxynucleotide against rev from humanimmunodeficiency virus type 1 in the adult male ratfollowing single injections and continuos infusion. AntisenseRes. Dev 4, 43-52.Iversen PL, Shu S, Meter A, and Zon G. (1992) Cellular uptakeand subcellular distribution of phosphorothioateoligonucleotides into cultured cells. Antisense Res. Dev 2,211-222.Iwasaka C, Tanaka K, Abe M, Sato Y. (1996) Ets-1 regulatesangiogenesis by inducing the expression of urokinase-typeplasminogen activator and matrix metalloproteinase-1 andmigration of vascular endothelial cells. J Cell Physiol 169,522-531Jekunen AP,Kairemo KJA. (1997) Inhibition of malignantangiogenesis. Cancer Treat Rev 23, 263-86.Jellinek D, Green LS, Bell C, Janjic N. (1994) Inhibition ofreceptor binding by high-affinity RNA ligands to vascularendothelial growth factor. Biochemistry 33, 10450-6Kaipainen A, Vlaykova T, Hatva E, Böhling T, Jekunen A,Pyrhönen S, Alitalo K. (1994) Enhanced expression of the tiereceptor tyrosine kinase messenger RNA in the vascularendothelium of metastatic melanomas. Cancer Res 54,6571-6577Kairemo KJA, Jekunen A, Karnani P. (1996) Modulation ofantibody kinetics by the cell membrane active agent Tween80 in vivo.Anticancer Res 16, 3542-3550Kairemo KJA, Jekunen AP, Tenhunen M. (1999) Essentials ofradionanotargeting using oligodeoxynucleotides. Gene TherMol Biol4, 171-176Kairemo KJA, Tenhunen M, Jekunen AP. (1996)Oligoradionuclidetherapy using radiolabelled antisenseoligodeoxynucleotide phosphorothioates. Anti-Cancer DrugDesign 11, 439-449Kairemo KJA,Tenhunen M, Jekunen AP. (1996) Dosimetry ofradionuclide therapy using radiophosphonated antisenseoligodeoxynucleotide phosphorothioates based on animalpharmacokinetic and tissue distribution data. Antisense NuclAcid Drug Dev 6, 215-220.Kairemo KJA, Thorstensen K,Mack M, Tenhunen M, JekunenAP. (1999) Ets-1 mRNA as target for antisense radiooligonucleotidetherapy in melanoma cells. Gene Ther MolBiol 4, 177-182Korhonen J, Partanen J, Armstrong E, Vaahtokari A, Elenius K,Jalkanen M, Alitalo K. (1992) Enhanced expression of the tiereceptor tyrosine kinase in cells during neovascularization.Blood 20, 2548-2555Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ,Radziejewski C, Compton D, McClain J, Aldrich TH,Papadopoulos N, Daly TJ, Davis S, Sato TN, YancopoulosGD. (1997) Angiopoietin-2, a natural antagonist for Tie2 thatdisrupts in vivo angiogenesis. Science 277, 55-60.Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, EgholmM, Hnatowich DJ. (1997) In vivo hybridization oftechnetium-99m-labeled peptide nucleic acid (PNA). J NuclMed 38, 907-913Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. (1997)Vascular endothelial growth factor/vascular permeabilityfactor is an autocrine growth factor for AIDS-Kaposisarcoma. Proc Natl Acad Sci U S A. 94, 979-84Risau W. (1997) Mechanisms of angiogenesis Nature 386, 671-4.Saleh M, Stacker SA, Wilks AF. (1996) Inhibition of growth ofC6 glioma cells in vivo by expression of antisense vascularendothelial growth factor sequence. Cancer Res 56, 393-401Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D,Trainor GL. (1994) Biodistribution and metabolism ofinternally 3 H-labeled oligonucleotides. I. Comparison of aphosphodiester and a phosphorothioate. Mol Pharmacol 45,932-943.Shoji Y, Akhtar S, Periasamy A. (1991) Mechanism of cellularuptake of modified oligonucleotides methylphosphonatelinkage. Nucl Acid Res 19, 5543-5550.Smyth AP, Rook SL, Detmar M, Robinson GS. (1997) Antisenseoligonucleotides inhibit vascular endothelial growthfactor/vascular permeability factor expression in normal22